Jump to content

NGS-Powered Quality Control: A New Standard for Biopharma

June 16, 2026
Arielle Mann

Quality control (QC) in biopharma is a continuous function across the full product lifecycle, from raw material qualification and early development through CMC, manufacturing, release testing, and post-release stability. At its core, QC encompasses the testing, monitoring, and documentation activities to ensure that therapeutic products are safe and effective. This is achieved by verifying that critical quality attributes (CQAs) related to identity, purity, and potency meet defined specifications and, if relevant, be GxP-compliant.

As biotherapeutic pipelines grow more complex, QC faces increasing pressure from higher data volumes and tighter timelines to heightened demands for traceability and compliance. Next-generation sequencing (NGS) has emerged as a powerful analytical tool for QC, offering GxP-ready workflows that support data integrity and streamlined compliance that are already recognized by leading regulatory agencies, including the FDA and EMA. Solutions such as Genedata Selector® enable organizations to operationalize these advances through GxP-compliant, scalable NGS workflows that elevate precision in quality control. 

The Cost of QC Failure in Biopharmaceutical Production

When Late-Stage Contamination Hits

In QC, when a deviation is detected, the batch fails. Root causes can include product instability or the detection of an adventitious agent. Such failures can significantly disrupt development timelines and trigger regulatory setbacks while the source and extent of the issue is investigated. A well-known example is when porcine circovirus type 1 DNA was detected in GSK’s human rotavirus vaccine, RotarixTM, which led to temporary suspension in several countries during extensive safety reviews.1 From a commercial standpoint, this directly impacts return on investment (ROI) by delaying time-to-market, reducing manufacturing throughput, and increasing overall production costs. These risks are compounded by the fact that bringing an investigational new drug (IND) to market typically takes more than a decade and costs approximately $2.6 billion.2,3 

To mitigate these challenges, organizations must implement QC pipelines with strong process controls grounded in quality by design (QbD) principles. This approach begins with a well-defined quality target product profile (QTPP), along with identified and continuously monitored CQAs. These are supported by critical material attributes (CMAs) and associated process parameters that ensure consistent control. Combined with GxP-compliant workflows, this approach strengthens regulatory readiness and ultimately improves manufacturing efficiency and commercialization outcomes. 

Beyond Contaminations: Genetic Quality Risks 

Many biotherapeutics are manufactured using living cells, requiring careful characterization of cell lines (including master and working cell banks) and vectors essential to ensure batch-to-batch consistency. This involves ongoing assessment of genetic stability and vector genome integrity, particularly for cell and gene therapies and antibody development where even minor sequence variations can affect efficacy and safety. 

To address this, comprehensive QC strategies should continuously monitor CQAs including mutations, truncations, recombination, integration events, and plasmid instability. NGS is well suited to these applications, having already been required by the FDA with additional NGS safety assessment being drafted,4-6 enabling detailed integration site analysis and broad genomic characterization.

Why NGS Is Becoming the Foundation of QC Workflows

NGS Enables Rapid, Unbiased, High-Resolution QC 

NGS is particularly well suited for QC as all potential quality attributes of the sample, known or not, must be investigated. Unlike targeted or assay-specific methods, NGS workflows are unbiased, capturing the full genetic content of a sample. This enables orthogonal detection of biological contaminants and comprehensive assessment of genetic stability across the genome or transcriptome.7-8 

In addition, NGS supports high-throughput workflows, allowing large volumes of samples to be analyzed efficiently and consistently. When integrated into end-to-end workflows spanning the full product lifecycle, automated NGS pipelines and standardized reporting drive highly sensitivity and accurate results. 

Regulatory Support for NGS 

As NGS becomes an industry-standard solution, extensive regulatory guidance already supports its use as a fit-for-purpose technology for safety testing.9-16 To enable adoption in regulated environments, NGS must be implemented within a validated framework, including operation within GxP workflows and adherence to requirements for electronic records, audit trails, and data integrity.17 When combined with standardized pipelines, automation, and compliant analysis, these practices enable NGS workflows that are reproducible, inspection-ready, and suitable for use throughout development and manufacturing. 

Bringing NGS In-House Delivers Maximum QC and Business Value 

Benefits of NGS with Genedata 

Bringing NGS in-house creates operational and strategic advantages for biopharma organizations. In-house sequencing capabilities provide higher data security to intellectual property by keeping sensitive data within controlled environments. In-house sequencing also improves data reliability and accelerates turnaround times compared to outsourcing. This enables faster decision-making, more efficient deviation investigations, and streamlined process optimization.

In-house NGS with Genedata additionally drives down long-term cost and enables stronger ROI by reducing per-sample costs and eliminating outsourcing fees. Integration with LIMS, advanced sample tracking, and automated QC pipelines enhances traceability, audit readiness, and data integrity for inspection-ready operations. 

Data Analysis and Processing: The Overlooked QC Bottleneck 

Automated reporting, version control, and robust audit trails are essential for translating complex sequencing data into defensible QC decisions. Genedata provides a validated platform for a wide range of assays including genetic stability and biosafety testing, while seamlessly connecting and automating sequencing data ingestion, automated analytics, sample management, compliance, and standardized reporting — all within a single environment.

Genedata enables fully traceable workflows through built-in versioning and audit trails, complimented by intuitive dashboards for clear pass/fail QC reporting. By eliminating fragmented workflows and reducing manual handoffs, Genedata ensures data integrity, reproducibility, and regulatory readiness across the entire therapeutic lifecycle. 


How Genedata Selector Supports QC Across the Entire Biopharma Production Journey 

  • Master Cell Bank (MCB) and Working Cell Bank (WCB) QC: Enables NGS-based assessments of genomic coverage, genetic drift, mutations, and adventitious agents, supporting consistent cell bank release and long-term stability across cell lines (e.g., CHO) 
  • Plasmid Characterization and Release Testing: Verifies full plasmid integrity, including complex or repetitive regions, and detects rearrangements, deletions, and mutations, while in-house NGS accelerates release timelines. 
  • mRNA Vaccine and Therapeutics QC: Assesses sequence identity, and purity, including poly(A) tail length, dsRNA impurities, and 5′/3′ end integrity, enabling comprehensive tracking. 
  • In-Process Control and Release Testing: Supports contamination screening, batch consistency analysis, and genetic drift monitoring within a unified, traceable QC workflow for regulatory-ready decisions. 

Partnering with QC and Manufacturing Teams to Deliver Reliable GxP-Ready NGS Workflows 

Genedata Selector streamlines the in-house validation of NGS data workflows and GxP-compliant reporting, delivering fully integrated QC processes that reduce risk, accelerate release timelines, and strengthen regulatory readiness. By enabling faster turnaround, lower per-sample costs, and providing deeper process insight through automated, traceable data analysis, the platform transforms raw sequencing data into confident QC decisions, minimizing late-stage setbacks and supporting consistent, compliant batch release. 

As a unified platform with a single validated pipeline spanning R&D through manufacturing, Genedata Selector provides a complete solution for biotherapeutics QC. Backed by deep expertise in data integrity and security, the Genedata Selector team ensures that NGS workflows operate within a robust, GMP-compliant environment to deliver confidence at every step.  

                                                
                                                                                 Learn More about Genedata Selector

FAQs

Regulatory-friendly NGS QC workflows are validated, traceable, and reproducible sequencing-based processes used to monitor critical quality attributes (CQAs) related to identity, purity, genetic stability, and viral safety of biotherapeutics throughout development and GMP manufacturing. These workflows operate within GxP environments and comply with regulatory expectations for data integrity, auditability, and electronic records, including FDA 21 CFR Part 11. 

Regulatory guidance such as ICH Q5A(R2), Ph. Eur. 2.6.41, and USP guidance on advanced analytical technologies explicitly recognize NGS as a fit-for-purpose alternative to traditional assays for biosafety testing and product characterization.To be inspection-ready, NGS QC workflows must include standardized pipelines, documented validation, controlled reference databases, and automated reporting. 

Genedata Selector enables regulatory-friendly NGS QC by providing an end-to-end, validation-ready software platform that automates sequencing data ingestion, analysis, and reporting while ensuring full traceability and data integrity in regulated environments. Additionally, using NGS workflows if fully supported by governing bodies such as the FDA with additional guidelines currently being drafted.

Modern pipelines use automated, standardized workflows that transform raw sequencing data into QC‑relevant outcomes such as contamination screening, genetic drift detection, vector integrity confirmation, and pass/fail batch decisions. These workflows must be version‑controlled, auditable, and consistently executed across programs and sites. While building a self-developed end‑to‑end NGS QC pipeline, organizations often use fragmented manual scripts, spreadsheets, and disconnected tools, which creates compliance risk and slows decision‑making. 

Genedata Selector supports this approach with an off-the-shelf solution equipped with wizard‑based Playbooks that automate validated NGS workflows from raw reads to standardized QC reports. As a single source of truth, the platform connects sequencing instruments, reference databases, analytics, and reporting within one GxP‑aligned environment, simplifying in‑house validation and long‑term maintenance of NGS QC pipelines.

Software supporting NGS‑based release testing must be purpose‑built for GMP environments, capable of handling complex sequencing data while delivering defensible, inspection‑ready results. Key requirements include automated analytics, standardized QC metrics, audit trails, role‑based access, and validated reporting aligned with regulatory guidance. Genedata Selector is specifically designed to support NGS‑based release testing across biologics, vaccines, and cell and gene therapies. 

It enables contamination screening, identity confirmation, genetic stability monitoring, and vector genome integrity assessment within a single validated platform. Built‑in version control and 21 CFR Part 11‑compliant audit trails ensure that release decisions are fully traceable and suitable for regulatory submission. By supporting multiple modalities and sequencing technologies, Genedata Selector allows organizations to qualify NGS‑based release testing once and reuse validated workflows across development and manufacturing programs.

QC pipeline automation in biopharma relies on replacing manual data handling and disconnected tools with integrated, workflow‑driven NGS analytics. Automation improves reproducibility, reduces human error, and significantly shortens turnaround times. 
Automated NGS QC pipelines typically include: 

  1. Standardized sample metadata capture
  2. Automated data loading from sequencers
  3. Pre‑configured analytics for contamination, variants, and integrity
  4. Rule‑based QC thresholds and pass/fail logic
  5. Automated, compliant reporting

Genedata Selector enables enterprise‑scale QC automation through configurable “Playbooks” and a centralized analytics platform that connects sequencing data, QC logic, and reporting. This approach has been shown to reduce NGS assay turnaround times by up to 90% while maintaining GMP readiness and inspection‑level documentation.

Under GMP, automated NGS QC reporting must produce consistent, standardized outputs with full traceability, versioning, and audit trails. Reports must clearly document methods, parameters, results, and QC decisions to support batch release and regulatory inspection. Genedata Selector provides automated, standardized QC reports generated directly from validated NGS workflows. 

Reports are generated within the same system used for data analysis, ensuring that no uncontrolled data manipulation occurs between analysis and documentation. Built‑in versioning tracks who performed each step, when it occurred, and which dataset and workflow version was used. This eliminates manual report assembly, reduces compliance risk, and ensures that QC documentation remains inspection‑ready across the entire therapeutic lifecycle.

Updates to ICH Q5A(R2) and Ph. Eur. 2.6.41 are accelerating the adoption of sequencing-based biosafety testing and promoting the replacement of animal assays with molecular methods. For this, biopharma QC software for in-house, GMP-ready NGS workflows is needed. At the software level, the focus has moved toward enterprise platforms that support multi-attribute methods (MAM), automation, integration with LIMS and ELNs, and scalable deployment across global sites. 

Genedata Selector offers off-the-shelf automation, improved validation support, and strengthened data integrity through enhanced version control and system connectivity. These advancements allow biopharma organizations to operationalize NGS as a core QC technology rather than a niche or experimental method. 

NGS reduces false positives and false negatives by providing unbiased, high‑resolution analysis of the full genetic content of a sample rather than relying on targeted assays with predefined assumptions. This is particularly important for detecting unknown or unexpected contaminants, mutations, or genetic rearrangements. When implemented with standardized pipelines, validated reference databases, and automated QC thresholds, NGS delivers consistent sensitivity and specificity across batches and programs. 

Detection of adventitious agents, full‑length sequence verification, and variant analysis improve confidence in QC decisions. Genedata Selector strengthens these advantages by enforcing controlled, reproducible analytics and eliminating manual interpretation steps that often introduce variability. This ensures that NGS‑based QC results are robust, defensible, and suitable for GMP decision‑making.


References: 

  1. Dubin, G.; et al.Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, RotarixTM:  Approach and outcome. Human Vaccines & Immunotherapeutics. 2013, 9(11), 2398–2408. 
     
  2. Saeed, A.; et al.Operational Excellence in Biopharma Research and Early Development. McKinsey & Company 2025. 
     
  3. The Cost to Develop an Approved New Drug Now Exceeds $2.5B. Applied Clinical Trials, 2014, 23(12). 
     
  4. Food and Drug Administration (FDA). Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry. (2020).
     
  5. Food and Drug Administration (FDA). Long Term Follow-Up After Administration of Human Gene Therapy Products; Guidance for Industry. (2020). 
     
  6. Food and Drug Administration (FDA). Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Guidance for Industry. 2026. 
     
  7. Xiao, Y,; et al.Application of next generation sequencing technology on contamination monitoring in microbiology laboratory. 2019, 1(1), 25-31.
     
  8. Hirai, T.; et al.Evaluation of next-generation sequencing performance for in vitro detection of viruses in biological products. Biologicals, 2024, 85, 101739. 
     
  9. ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH: Q5A Guideline on Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin: Training Materials Module 0-3 0-3; 2025. 
     
  10. Food and Drug Administration (FDA). Process Validation: General Principles and Practices. (2011).
     
  11. Food and Drug Administration (FDA). Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics. (2018). 
     
  12. USP. Vaccines for Human Use—Viral Vaccines. In: USP–NF Online. Rockville, MD: USP; 2025.
     
  13. European Medicines Agency (EMA). Guideline on Principles for the Regulatory Acceptance of 3Rs (Replacement, Reduction, Refinement) Testing Approaches. 2016. www.ema.europa.eu/en/documents/scientific-guideline/guideline-principles-regulatory-acceptance-3rs-replacement-reduction-refinement-testing-approaches_en.pdf 
     
  14. FDA Modernization Act 2.0, S. 5002, 117th Cong. (2022) 
     
  15. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes, OJ L 276, 20.10.2010, p. 33–79. 
     
  16. European Directorate for the Quality of Medicines & HealthCare (EDQM). EPC adopts a cutting-edge HTS chapter to enhance viral contaminant detection in biological products. 2025. www.edqm.eu/en/-/epc-adopts-cutting-edge-hts-chapter-to-enhance-viral-contaminant-detection-in-biological-products 
     
  17. U.S. Food and Drug Administration (FDA). Electronic Records; Electronic Signatures (21 CFR Part 11). 2026. www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11